Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

INTRODUCTION: The Cancer and Leukemia Group B (CALGB) conducted a multi-center phase II trial to evaluate the efficacy and safety of vatalanib in previously untreated patients with malignant mesothelioma and to evaluate potential biomarkers of disease response (CALGB 30107). METHODS: Treatment consi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung Cancer
Hauptverfasser: Jahan, Thierry, Gu, Lin, Kratzke, Robert, Dudek, Arkadiusz, Otterson, Gregory A., Wang, Xiaofei, Green, Mark, Vokes, Everett E., Lee Kindler, Hedy
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778731/
https://ncbi.nlm.nih.gov/pubmed/22197613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2011.11.014
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge